Lung cancer is one of the leading causes of cancer mortality around the world. The progression of lung cancer is often marked by the metastasis, which is a progress where the lung cancer cells start to spread out to other organs and systems in our human body. This progression is always marked by the scientists as the sign of the mortality of the patient. Epithelial-mesenchymal transition (EMT) is a critical process in the development of lung cancer, contributing to metastasis and resistance to therapy. EMT facilitates the invasion of the cancer cell, and prevents the apoptosis. EMT also enhances tumor cell survival, and resistance to the conventional chemotherapy or target treatment. It is an important process that leads to the spread of cancer cell and cause death. This essay focuses on the molecule transforming growth factor-beta (TGF-β), which plays a central role in regulating EMT. In particular, mutations in TGF-β receptors significantly impact this process. This essay examines the effects of TGF-β receptor mutations on EMT in lung cancer, analyzing common and emerging mutations, their functional consequences, and the potential therapeutic implications. By exploring the altered signaling pathways and their effects on EMT markers, this study provides insights into the role of TGF-β receptor mutations in lung cancer metastasis and prognosis.
Research Article
Open Access